GoldenGolden
Roche Holding

Roche Holding

Roche is a multi-national healthcare company that develops pharmaceuticals and diagnostics that improve people's lives

Roche is a multi-national healthcare company that develops pharmaceuticals and diagnostics that improve people's lives. The company was founded in 1986 by Fritz Hoffman-La Roche, in Basel, Base-Stadt, Switzerland.

The company has the mission to provide urgent delivery of medical solutions to improve patients lives. The company has created several medical products such as Alecensa, Avastin, Bactrim, Dilatrend, Fuzeon, Hemlibra, Lucentusm Beupogen, Pegasys, Viracept, Xolair, and Actemra.

COVID-19 treatment and diagnostics

Since the outbreak of COVID-19, China approved the use of Roche's Actemra for patients with severe cases of coronavirus. The drug has the ability to prevent overreactions in the immune system, which is the leading cause of organ failure deaths in some coronavirus patients. The drug is part of a clinical trial that would be conducted until May, 2020.

Actemra is used as an anti-inflammation drug, and works to treat coronavirus patients with severe lung damage and high IL-6 levels. The drug was originally administered as a treatment of rheumatoid arthritis. The drug will be administered in the US, Italy, Switzerland, France, and Germany.

For COVID-19 diagnostics the FDA granted emergency use authorization (EUA) for a nucleic acid detection test (RT-PCR) that runs on Roche’s cobas 6800/8800 automated systems which can test 4,128 (8800 system) or 1,400 patients (6800 system) per day and provide results in 4 hours. The test is also available in Europe in countries that accept CE marking. The cobas SARS-CoV-2 test is the third test granted emergency approval by the FDA and the first commercially available one. The cobas systems were launched in 2014 and are widely available globally. As of March, 2020 there are 695 of the 6800 instruments and 132 of the 8800 instruments installed.

Timeline

Funding rounds

People

Name
Role
LinkedIn

Aaron Blaisdell

Employee

Adam Babik

Employee

Adam Pettler

Employee

adekunle kehinde

Employee

Adrian Nowicki

Employee

Agnieszka Wasińska

Employee

Ajan Reginald

Employee

Alain Bindels

Employee

Aleksandar Kontrec

Employee

Alex Codik

Employee

Alexander Gawehns

Employee

Alexander Lifke

Employee

Alexander Sennhauser

Employee

Alexandra Kostakis

Employee

Alfredo Zambonini

Employee

Aline Cueni

Employee

Alok Dube

Employee

Alvaro Aller Garcia

Employee

Amy Divaraniya

Employee

Amy Nicole Nayar (Grudzinski) PharmD, MS

Employee

Ana Jimenez

Employee

Andrea Ramos

Employee

Andrea Sancho

Employee

Andronache Daniel

Employee

Andrzej Dybionka

Employee

Page 1 of 14
...

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Roche

Fritz Hoffman-La Roche

Basel, Base-Stadt, Switzerland

Healthcare and drug development solutions

News

Title
Author
Date
Publisher
Description
Guy Faulconbridge
May 14, 2020
IN
Britain is in talks with Swiss drugmaker Roche Holding AG to buy an accurate COVID-19 antibody test, following the lead of the European Union and United States, which had already given preliminary approval to the tests.
John Miller
May 11, 2020
U.S.
Fritz Gerber, the long-time head of Roche Holding who helped transform the Swiss company from an image-tarnished vitamins, drugs and chemicals conglomerate into a biotechnology and diagnostics giant, has died at the age of 91.
Reuters Editorial
March 23, 2020
IN
It could take at least a couple of weeks, if not months, for the United States to implement broad testing for coronavirus, Roche Holding AG Chief Executive Officer Severin Schwan said in an interview with CNBC on Monday.
John Revill
April 3, 2019
U.S.
Roche Holding said its effort to expand in gene therapy via the $4.3 billion takeover of Spark Therapeutics remained on track despite failing to get enough votes to clinch the deal and as U.S. regulators continued scrutinizing it.
Reuters Editorial
April 3, 2019
U.S.
Roche Holding has extended until May 2 its $4.3 billion offer for U.S. gene therapy specialist Spark Therapeutics, the Swiss drugmaker said after getting 29.4 percent of Spark's shares in a tender originally due to end on Wednesday.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.